Compile Data Set for Download or QSAR
maximum 50k data
Found 2444 Enz. Inhib. hit(s) with Target = 'Somatostatin receptor type 4'
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311970(US10166214, Example 106 | US10675268, Example 106)
Affinity DataEC50:  0.100nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311970(US10166214, Example 106 | US10675268, Example 106)
Affinity DataEC50:  0.100nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311957(US10166214, Example 93 | US10675268, Example 93 | ...)
Affinity DataEC50:  0.100nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311957(US10166214, Example 93 | US10675268, Example 93 | ...)
Affinity DataEC50:  0.100nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50597579(CHEMBL5197201)
Affinity DataEC50:  0.100nMAssay Description:Agonist activity at recombinant human SST4 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production measured...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM506557(US11045457, Example 157)
Affinity DataEC50:  0.126nMAssay Description:This cell-based assay measures the ability of compounds to inhibit forskolin stimulated cAMP in CHO-K1 cells overexpressing SSTR4. CHO-K1 cells overe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM506589(US11045457, Example 190)
Affinity DataEC50:  0.158nMAssay Description:This cell-based assay measures the ability of compounds to inhibit forskolin stimulated cAMP in CHO-K1 cells overexpressing SSTR4. CHO-K1 cells overe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataEC50:  0.200nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataEC50:  0.200nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50597589(CHEMBL5209180)
Affinity DataEC50:  0.200nMAssay Description:Agonist activity at recombinant human SST4 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production measured...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM523757(US11136312, Compound MM-I-87)
Affinity DataEC50:  0.200nMAssay Description:Agonist activity at recombinant human SST4 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production measured...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311973(US10166214, Example 109 | US10675268, Example 109)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM312007(US10166214, Example 143 | US10675268, Example 143)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311944(US10166214, Example 80 | US10675268, Example 80 | ...)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311944(US10166214, Example 80 | US10675268, Example 80 | ...)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311967(US10166214, Example 103 | US10675268, Example 103)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM312007(US10166214, Example 143 | US10675268, Example 143)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM523756(US11136312, Compound MM-I-83)
Affinity DataEC50:  0.300nMAssay Description:Agonist activity at recombinant human SST4 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production measured...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311973(US10166214, Example 109 | US10675268, Example 109)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311994(US10166214, Example 130 | US10675268, Example 130)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50597576(CHEMBL5180543)
Affinity DataEC50:  0.300nMAssay Description:Agonist activity at recombinant human SST4 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production measured...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311994(US10166214, Example 130 | US10675268, Example 130)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311967(US10166214, Example 103 | US10675268, Example 103)
Affinity DataEC50:  0.300nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM506615(US11045457, Example 216)
Affinity DataEC50:  0.398nMAssay Description:This cell-based assay measures the ability of compounds to inhibit forskolin stimulated cAMP in CHO-K1 cells overexpressing SSTR4. CHO-K1 cells overe...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081055(CHEMBL3421843 | US10166214, Example 49 | US1067526...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311939(US10166214, Example 75 | US10675268, Example 75)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311956(US10166214, Example 92 | US10675268, Example 92)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081058(CHEMBL3421842 | US10166214, Example 22 | US1067526...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081055(CHEMBL3421843 | US10166214, Example 49 | US1067526...)
Affinity DataEC50:  0.400nMAssay Description:Agonist activity at human somatostatin 4 receptor expressed in H4 cells assessed as inhibition of forskolin-induced intracellular cAMP accumulation i...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081058(CHEMBL3421842 | US10166214, Example 22 | US1067526...)
Affinity DataEC50:  0.400nMAssay Description:Agonist activity at human somatostatin 4 receptor expressed in H4 cells assessed as inhibition of forskolin-induced intracellular cAMP accumulation i...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM312048(US10166214, Example 184 | US10675268, Example 184)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311939(US10166214, Example 75 | US10675268, Example 75)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311956(US10166214, Example 92 | US10675268, Example 92)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311969(US10166214, Example 105 | US10675268, Example 105)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311990(US10166214, Example 126 | US10675268, Example 126 ...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311992(US10166214, Example 128 | US10675268, Example 128 ...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081058(CHEMBL3421842 | US10166214, Example 22 | US1067526...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50081055(CHEMBL3421843 | US10166214, Example 49 | US1067526...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM312048(US10166214, Example 184 | US10675268, Example 184)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311969(US10166214, Example 105 | US10675268, Example 105)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311990(US10166214, Example 126 | US10675268, Example 126 ...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311992(US10166214, Example 128 | US10675268, Example 128 ...)
Affinity DataEC50:  0.400nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311888(US10166214, Example 24 | US10675268, Example 24 | ...)
Affinity DataEC50:  0.5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50597581(CHEMBL5183772)
Affinity DataEC50:  0.5nMAssay Description:Agonist activity at recombinant human SST4 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production measured...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311941(US10166214, Example 77 | US10675268, Example 77)
Affinity DataEC50:  0.5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311941(US10166214, Example 77 | US10675268, Example 77)
Affinity DataEC50:  0.5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311888(US10166214, Example 24 | US10675268, Example 24 | ...)
Affinity DataEC50:  0.5nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM50546560(CHEMBL4778342)
Affinity DataEC50:  0.501nMAssay Description:Agonist activity at human SST4More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311876(US10166214, Example 12 | US10675268, Example 12)
Affinity DataEC50:  0.600nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311946(BDBM311964 | US10166214, Example 82 | US10675268, ...)
Affinity DataEC50:  0.600nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 2444 total ) | Next | Last >>
Jump to: